A new mouse model mimicking the liver symptoms of myotonic dystrophy type 1 — the most prevalent form of adult-onset muscular dystrophy — provides insight into why patients develop fatty liver disease and display hypersensitivity to medications, making treatment difficult. The new model opens avenues for screening new medications for liver toxicity prior to patient trials.
Categories
Recent Posts
- Clinical Research Alert: Phase 1b Study of SRD-001 in Adults with DMD-Related Cardiomyopathy
- Holiday Gift Wrapping Made Easier: Accessible Tips & Tricks
- Planning a ‘Krank’ Christmas and getaway with accessibility in mind
- Protected: Honoring Every Journey in Duchenne and Becker: Advancing Therapies, Access, and Care For All
- DMD treatment Kymbee launches with support program for patients